GEN Exclusives

More »

GEN News Highlights

More »
Sep 6, 2012

Sigma-Aldrich to Distribute AB Sciex Consumables

  • Sigma-Aldrich agreed to distribute worldwide AB Sciex’ portfolio of mass spectrometry-based tagging chemistries. The consumables, sold as SCIEX iChemistryTM Solutions, are intended for proteomics applications in basic research and applied markets.

    According to Sigma-Aldrich, the OEM agreement strengthens its mass spectrometry reagent business, reflects the company’s commitment to expanding its mass spec applications for the life sciences, and lays groundwork for a partnership with AB Sciex that will provide the basis for future joint development of mass spec consumables.

    The accord makes available all consumbles for quantitative proteomics and small molecule metabolite quantitation through Sigma-Aldrich. The company said the reagents complement its existing reagents portfolio for mass spectrometry.

    “Particularly in the Asia-Pacific region, this distribution agreement will provide the research community with easy and reliable access to AB Sciex’s unique reagents and consumables for mass spectrometry applications,” Josef Zihlmann, vp, marketing for Sigma-Aldrich, said in a statement.

    “In addition to establishing a complete toolset for mass spectrometry research with AB Sciex, we are continually adding to our collection of 60,000 antibodies that enable researchers to accurately discern dynamic states of proteins in key pathways throughout the proteome,” Zihlmann added.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »